van der A D L, Peeters P H M, Grobbee D E, Roest M, Marx J J M, Voorbij H M, van der Schouw Y T
University Medical Center Utrecht, the Netherlands.
Eur J Clin Invest. 2006 Oct;36(10):682-90. doi: 10.1111/j.1365-2362.2006.01711.x.
Although heterozygosity for the C282Y mutation in the HFE gene has been associated with an increased risk of cardiovascular events, epidemiological studies remain inconclusive. The aim of the present study was to obtain further evidence as to whether HFE mutations are associated with risk of coronary heart disease (CHD) in middle-aged women. We used data of a cohort of 15 236 Dutch middle-aged women to investigate whether C282Y carriers and H63D carriers are at increased risk of coronary heart disease compared with non-carriers.
Women were included in the study between 1993 and 1997 and were followed until 1 January 2000 for cardiovascular events. HFE genotyping was performed on all 211 coronary heart disease cases and a randomly selected sample from the baseline cohort (n = 1526). A weighted Cox proportional hazards model was used to estimate crude, age-adjusted and multivariate adjusted hazard ratios for C282Y and H63D carriership in relation to coronary heart disease.
Compared with non-carriers, those that carried the C282Y allele were not at increased risk for CHD (HR = 1.25, 95% CI = 0.74-2.09). Neither did we find an association between the H63D mutation and CHD risk (HR = 0.73, 95% CI = 0.43-1.24).
Our results are in accordance with similar studies to date, for which we present a meta-analysis. HFE mutations appear not to affect the risk of coronary heart disease.
尽管HFE基因C282Y突变的杂合性与心血管事件风险增加有关,但流行病学研究尚无定论。本研究的目的是进一步证实HFE突变是否与中年女性冠心病(CHD)风险相关。我们使用了15236名荷兰中年女性队列的数据,以调查C282Y携带者和H63D携带者与非携带者相比,冠心病风险是否增加。
1993年至1997年间将女性纳入研究,并随访至2000年1月1日,观察心血管事件。对所有211例冠心病病例和基线队列中随机抽取的样本(n = 1526)进行HFE基因分型。采用加权Cox比例风险模型估计C282Y和H63D携带者相对于冠心病的粗风险比、年龄调整风险比和多变量调整风险比。
与非携带者相比,携带C282Y等位基因者患冠心病的风险并未增加(HR = 1.25,95%CI = 0.74 - 2.09)。我们也未发现H63D突变与冠心病风险之间存在关联(HR = 0.73,95%CI = 0.43 - 1.24)。
我们的结果与迄今为止的类似研究一致,我们对此进行了荟萃分析。HFE突变似乎不影响冠心病风险。